GUANIDINE HYDROCHLORIDE
LOE ApproachingNDAORALTABLET
Approved
Oct 1939
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Guanidine hydrochloride is an oral tablet small molecule approved in 1939 by Merck & Co. with an unknown mechanism of action and indication profile. The drug is currently approaching loss of exclusivity (LOE), indicating a long-established legacy product in the mature stage of its lifecycle.
LOE Approaching
Competitive pressure at 30% suggests moderate market fragmentation; LOE approaching signals declining team investment and potential restructuring within the brand organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for this product line, reflecting its LOE status and declining commercial focus. Career opportunities are limited to defensive roles managing brand decline or generic transition support.
Brand ManagerMedical Science Liaison
Worked on GUANIDINE HYDROCHLORIDE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.